Why IMU is a multi multi bagger, page-20424

Good Morning All,

Lots of great posts from many people regarding disclosures & potential incoming ANNs, thanks I appreciated reading.

So as @Harry58 has found, we are expecting a presentation upcoming in Vaxinia for GI Cancers, and it appears that quite a lot of us think that this may be a reason for no update forthcoming before hand. Thanks Harry! @davybabyk has recently linked your post.

We are still in updosing cohorts across multiple arms of the Vaxinia trial & this trial is across multiple indications for solid tumours. A few of us feel that an ANN is probably due soon in regards to clearing further cohorts.

I feel that reaching OBD is going to be very significant, and they will need to do the data cut for the FDA for updosing anyway.

To me - same trial, but different price sensitive information than may be presented in the CF33-HNIS poster in GI cancers.

So for sure, as Davy says be cautious - but I wouldn’t be ruling anything out at this point in time, right before a major investment preso in the US as well. If that happens then perfect timing isn’t it? I think we all deserve a little luck on our side quite frankly.

Are the stars aligning for us after a very tough year for investors? Maybe so & Macros looking encouraging as is quite a bit of M&A activity in Pharma news.

Have a great day folks